) to $38 from $36 after the company beat earnings estimates last week. Jefferies rates Nu Skin as a Buy. In the report, Jefferies writes, "We are once again raising estimates, as NUS continues to enjoy the strong momentum from the late 2009 launch of its ageLOC personal care regimen. Upcoming ageLOC nutritional launches should keep momentum intact. In addition to strong sales growth, operating margin expansion is a couple years ahead of plan." [We are] "Raising 2010E from $1.95 to $2.05, $0.09 above the upper end of mgt's range, which was raised to $1.90-$1.96 with the release, and also above consensus of $1.90." Shares of Nu Skin closed at $28.48 on Friday.